Search

Home > New FDA Approvals > 034 - FDA approves first two-drug regimen for certain patients with HIV; sBLA submitted to FDA for daratumumab in front line multiple myeloma; FDA steps to promote development of generic versions of opioids formulated to deter abuse


	Podcast:		New FDA Approvals
	Episode:		034 - FDA approves first two-drug regimen for certain patients with HIV; sBLA submitted to FDA for daratumumab in front line multiple myeloma; FDA steps to promote development of generic versions of opioids formulated to deter abuse
	Category:		Science & Medicine
	Duration:		00:06:53
	Publish Date:		2017-11-22 07:00:00
	Description:		November 22, 2017 0:30 FDA approves first two-drug regimen for certain patients with HIV https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm586305.htm 2:10 Supplemental Biologics License Application submitted to FDA for Daratumumab in Front Line Multiple Myeloma http://ir.genmab.com/releasedetail.cfm?ReleaseID=1049538 3:02 FDA steps to promote development of generic versions of opioids formulated to deter abuse https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm586117.htm If we can help with any medical writing, please reach out to us at info@nascentmc.com Our US-based company, Nascent Medical, LLC, has a team of over 100 PhD-/MD-level writers who can write about any medical, scientific or technical topic. We charge a flat rate and provide an upfront estimate. Our turn around times can be as short as 1 to 2 days depending on the length of the project, and we don't charge extra for our speediness. Have you updated your blog or posted any press releases lately? That's a small project that some clients like to test us out with to start. We do the following types of writing, including but not limited to: -Video and virtual reality script writing -eLearning scripts -Medical education -Webinar slide creation -Manuscripts -Slidesets -Manuscripts -Press releases -Blog posts -Annual reports -Proposals -White papers -Web content -Posters -Sales training materials
	Total Play:		0